Search Results - "Azim, Hamdy"

Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology by Azim, Hamdy A., Abdel-Malek, Raafat, Kassem, Loay

“…Brain metastasis is a devastating complication of breast cancer. We conducted a retrospective analysis among patients presenting with early and metastatic…”
Get full text

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population by De Laurentiis, Michelino, Borstnar, Simona, Campone, Mario, Warner, Ellen, Bofill, Javier Salvador, Jacot, William, Dent, Susan, Martin, Miguel, Ring, Alistair, Cottu, Paul, Lu, Janice, Ciruelos, Eva, Azim, Hamdy A., Chatterjee, Sanjoy, Zhou, Katie, Wu, Jiwen, Menon-Singh, Lakshmi, Zamagni, Claudio

“…Purpose CompLEEment-1 is a phase 3b trial in an expanded patient population with hormone receptor-positive (HR +), human epidermal growth factor…”
Get full text

Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis by Azim, Hamdy A., Shohdy, Kyrillus S., Elghazawy, Hagar, Salib, Monica M., Almeldin, Doaa, Kassem, Loay

“…In patients with metastatic triple-negative breast cancer (TNBC), programmed death-ligand 1 (PD-L1) expression has been demonstrated to predict response to…”
Get full text

Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies by Azim, Hatem A, Santoro, Luigi, Pavlidis, Nicholas, Gelber, Shari, Kroman, Niels, Azim, Hamdy, Peccatori, Fedro A

“…Abstract Background Due to the rising trend of delaying pregnancy to later in life, more women are diagnosed with breast cancer before completing their…”
Get full text

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study by Gligorov, Joseph, Pivot, Xavier, Ataseven, Beyhan, De Laurentiis, Michelino, Jung, Kyung Hae, Manikhas, Alexey, Abdel Azim, Hamdy, Gupta, Kushagra, Alexandrou, Ari, Herraez-Baranda, Luis, Tosti, Nadia, Restuccia, Eleonora

“…To report the final results of the 5-year follow-up of the non-randomized SafeHER Phase III study (NCT01566721) describing the safety, tolerability, and…”
Get full text

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer by Lu, Yen-Shen, Mahidin, Eznal Izwadi Bin Mohd, Azim, Hamdy, Eralp, Yesim, Yap, Yoon Sim, Im, Seock-Ah, Rihani, Julie, Gokmen, Erhan, El Bastawisy, Ahmed, Karadurmus, Nuri, Lim, Yueh Ni, Lim, Chun Sen, Duc, Le Thanh, Chung, Wei-Pang, Babu, K. Govind, Penkov, Konstantin, Bowles, James, Alfaro, Teresa Delgar, Wu, Jiwen, Gao, Melissa, Slimane, Khemaies, El Saghir, Nagi S., Alsayed, Adher, El Bastawisy, Ahmed, Gogia, Ajay, Charoentum, Chaiyut, Goswami, Chanchal, Liu, Chien-Ting, Lim, Chun Sen, Artamonova, Elena, Gokmen, Erhan, Namal, Esat, Mohd Mahidin, Eznal Izwadi, Farhat, Fadi, Li Tze, Flora Chong, Başaran, Gül, Harputluoglu, Hakan, Azim, Hamdy Abdel, Abdelrazeq, Hikmat, ElGhazaly, Hesham, Babu, K. Govind, Penkov, Konstantin, Duc, Le Thanh, Tseng, Ling-Ming, Osmanova, Liudmila, Zhukova, Ludmila, Konatum, Meher Lakshmi, Nahit Şendur, Mehmet Ali, Dai, Ming-Shen, Ayoubi, Mona, El-Saghir, Nagi, Prasongsook, Naiyarat, Parinyanitikul, Napa, Volkov, Nikita, Karadurmus, Nuri, Sunpaweravong, Patrapim, Siang Ang, Peter Cher, Voon, Pei Jye, Gaafar, Rabab, Motagaly, Rasha Abdel, Khanyile, Richard, Goksu, Sema Sezgin, Chen, Shin-Cheh, Gupta, Sudeep, Lynette Ngo, Su Mien, Choong, Swee Hsia, Huang Tan, Terence Aik, Demirci, Umut, Chung, Wei-Pang, Hsieh, Wen-Son, Lu, Yen-Shen, Eralp, Yesim, Yap, Yoon Sim, Chang, Yuan-Ching, Lim, Yueh Ni

“…PURPOSE A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT)…”
Get full text

Integrating PARP inhibitors into the management of breast cancer: where are we? by Azim, Hamdy A., Kassem, Loay, Azim Jr, Hatem

Get full text

Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial by Azim, Hamdy A, Saleh, Mariam A, Essam Eldin, Passant, Abdelhafeez, Ahmed A M, Hassan, Mohamed, Kassem, Loay

“…First line endocrine therapy is the gold standard for advanced estrogen receptor positive, human epidermal growth factor receptor 2 negative breast cancer…”
Get full text

Tailoring neo/adjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations by Elghazaly, Hesham, Azim, Hamdy, Rugo, Hope, Cameron, David, Swain, Sandra, Curigliano, Giuseppe, Harbeck, Nadia, Tripathy, Debu, Arun, Banu, Aapro, Matti, Piccart, Martine, Cardoso, Fatima, Gligorov, Joseph, Elghazawy, Hagar, El Saghir, Nagi, Penault-Llorca, Frederique, Perez, Edith, Poortmans, Philip, Abdelaziz, Hany, El-Zawahry, Heba, Kassem, Loay, Sabry, Mohamed, Viale, Giuseppe, Al-Sukhun, Sana, Gado, Neven, Leung, Jessica, Ezz Elarab, Lobna, Cardoso, Maria João, Abdel Karim, Khaled, Foheidi, Meteb, Elmaadawy, Merit, Conte, Pierfranco, Selim, Ashraf, Kandil, Alaa, Kamal, Rasha, Paltuev, Ruslan, Guarneri, Valentina, Abulkhair, Omalkhair, Zakaria, Omar, Golshan, Mehra, Orecchia, Roberto, Elmahdy, Manal, Abdel-Aziz, Ahmed, Eldin, Nermean Bahie

“…Abstract Background The management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the…”
Get full text

Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations by Elghazaly, Hesham, Azim, Hamdy A., Rugo, Hope S., Cameron, David, Swain, Sandra M., Curigliano, Giuseppe, Harbeck, Nadia, Tripathy, Debu, Arun, Banu, Aapro, Matti, Piccart, Martine, Cardoso, Fatima, Gligorov, Joseph, Elghazawy, Hagar, El Saghir, Nagi S., Penault‐Llorca, Frederique, Perez, Edith A., Poortmans, Philip, Abdelaziz, Hany, El‐Zawahry, Heba M., Kassem, Loay, Sabry, Mohamed, Viale, Giuseppe, Al‐Sukhun, Sana, Gado, Neven, Leung, Jessica W. T., Ezz Elarab, Lobna, Cardoso, Maria João, Abdel Karim, Khaled, Foheidi, Meteb, Elmaadawy, Merit M., Conte, Pierfranco, Selim, Ashraf S. M., Kandil, Alaa, Kamal, Rasha M., Paltuev, Ruslan M., Guarneri, Valentina, Abulkhair, Omalkhair, Zakaria, Omar, Golshan, Mehra, Orecchia, Roberto, ElMahdy, Manal, Abdel‐Aziz, Ahmed M., Eldin, Nermean Bahie

“…Background The management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the systemic…”
Get full text

Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study by Jung, Kyung Hae, Ataseven, Beyhan, Verrill, Mark, Pivot, Xavier, De Laurentiis, Michelino, Al‐Sakaff, Nedal, Lauer, Sabine, Shing, Mona, Gligorov, Joseph, Azim, Hamdy A.

“…Background This SafeHer subgroup analysis assessed the safety of fixed‐dose subcutaneous trastuzumab (H SC) as an adjuvant therapy in HER2‐positive early…”
Get full text

Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population by De Laurentiis, Michelino, Borstnar, Simona, Campone, Mario, Warner, Ellen, Bofill, Javier Salvador, Jacot, William, Dent, Susan, Martin, Miguel, Ring, Alistair, Cottu, Paul, Lu, Janice, Ciruelos, Eva, Azim, Hamdy A., Chatterjee, Sanjoy, Zhou, Katie, Wu, Jiwen, Menon-Singh, Lakshmi, Zamagni, Claudio

Get full text

Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis by Azim, Hamdy A, Elghazawy, Hagar, Ghazy, Ramy M, Abdelaziz, Ahmed H, Abdelsalam, Marwa, Elzorkany, Amira, Kassem, Loay

“…Breast cancer (BC) is the most common cancer among Egyptian females. No current national cancer database is available in Egypt to provide reliable data on the…”
Get full text

Breast cancer in Egypt, China and Chinese: statistics and beyond by Azim, Hamdy A, Ibrahim, Amal S

Get full text

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer by Mubarak, Nabil, Gaafar, Rabab, Shehata, Samir, Hashem, Tarek, Abigeres, Dani, Azim, Hamdy A, El-Husseiny, Gamal, Al-Husaini, Hamed, Liu, Zhixin

“…Maintenance therapy for non-small cell lung cancer (NSCLC) aims to extend disease control after first-line chemotherapy with active and well-tolerated agents…”
Get full text

The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer by Azim, Hamdy A., Loutfy, Samah A., Azim, Hatem A., Kamal, Nermin S., Abdel Fattah, Nasra F., Elberry, Mostafa H., Abdelaziz, Mohamed R., Abdelsalam, Marwa, Aziz, Madonna, Shohdy, Kyrillus S., Kassem, Loay

“…Background Deleterious germline mutations in BRCA1 and BRCA2 genes are associated with a high risk of breast and ovarian cancer. In many developing countries,…”
Get full text

Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort by Aboelhassan, Rasha, Sobeih, Mohamed Emam, El-Din, Mohamed Alm, Ghali, Ramy R., El-Din, Ibtessam Saad, Khorshid, Ola, Mokhtar, Mohsen, Rabea, Ahmed Magdy, Belal, Abdelaziz, Azim, Hamdy A., Abdullah, Mohamed, Elnahas, Tamer, Tawfik, Hesham, Abdelwahab, Sherif, Elsaid, Amr Abdelaziz, Hashem, Tarek, Mancy, Mohamed, Farag, Heba

“…Background: Stage III non-small cell lung cancer (NSCLC) being highly heterogeneous requires multimodal therapeutic strategies for optimal management. We…”
Get full text

Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin by Abdel Azim, Hamdy, Kassem, Loay, Shohdy, Kyrillus Samaan, Eshaak, Boules, Anis, Shady Elia, Kamal, Nermine Shawky

“…The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with…”
Get full text

Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis by Azim, Hamdy A., Shohdy, Kyrillus S., Kaldas, David F., Kassem, Loay, Azim, Hatem A.

“…Background: The benefit of adding ovarian function suppression (OFS) to tamoxifen in the adjuvant treatment of premenopausal women with breast cancer is…”
Get full text

Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer by Azim, Hamdy A, Kassem, Loay, Treilleux, Isabelle, Wang, Qing, El Enein, Mona Abu, Anis, Shady E, Bachelot, Thomas

“…Abstract BACKGROUND: The PI3K/AKT/mTOR pathway alterations have been shown to play significant roles in the development, progression, and metastatic spread of…”
Get full text